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4executive summary
Over the last decade UK scientists, clinicians and 
industrialists have expressed growing concern 
about the ‘translational gap’ between basic 
scientific discovery and innovation that will benefit 
patients. High quality clinical research is key to 
closing this gap and underpins innovation and 
improvement in health services. Clinical research 
is also central to the UK’s pharmaceutical, 
biotechnology and medical devices industries, 
which combined are an essential component of 
the UK’s economy. Yet the UK clinical research 
base is increasingly under threat from global 
competition and the time and cost of research 
and development continues to be a major 
challenge. The successful management and 
organisation of clinical research projects will be 
pivotal to overcoming these challenges in the 
future. 
This report presents the findings from a 2-year 
EPSRC-funded study1 which was undertaken 
to systematically explore the challenges of 
organising and managing different models of 
clinical research.
Aim: To identify the key social, organisational and 
managerial factors that influence clinical research 
projects with a view to improving the clinical 
research process and reducing the costs and 
risks of development. 
The study employed a multi-method design 
incorporating:
 
Phase 1
i. A systematic literature review of previous work 
in this area, containing 129 articles. 
ii. 57 interviews with key stakeholders which 
focused on the challenges of conducting 
different types of clinical research in the UK. 
 
1  “The Management & Organisation of Clinical Trials” (RIBK 9223) – The research 
was funded by the Engineering and Physical Sciences Research Council (EPSRC) via 
the Warwick Innovative Manufacturing Research Centre.
iii. A large scale survey generating data on the 
management of 247 clinical research projects 
conducted in the UK. 
Major findings 
There has been an overall improvement in the 
proportion of projects that complete within time 
over the last decade. However, this improvement 
is largely related to improvements in time to 
recruit patients, whilst the project set-up stage 
continues to be a significant challenge. There is a 
slight drop in the proportion of projects that reach 
the anticipated recruitment target expected from 
UK sites within agreed time frames.
Projects led by pharmaceutical companies 
were more likely to complete on time and to 
patient recruitment targets, as compared to 
other projects led by commercial organisations 
and those led by non-commercial research 
groups. 45% of pharmaceutical-led projects 
completed on time, compared with 32% of 
non-commercial studies, and 24% of projects 
led by other commercial organisations. 68% 
of pharmaceutical-led projects completed on 
budget, compared to 64% of non-commercial 
studies and 48% of projects led by other 
commercial organisations.
From the analysis of the data derived from both 
phases of the study, the greatest challenges 
affecting the management of clinical research 
were found around four areas: 
•	 Regulation & Governance: Successfully 
completing the governance approval process 
was identified as a particular challenge for 
project management. In particular, different 
types of research organisation naturally conduct 
different models of research, all of which 
experience dissimilar pressures in managing 
the regulatory and governance process. 
Phase 2
5 Project 
management 
requires the 
development 
of practical, 
nuanced 
knowledge
Researchers that do not adopt standard 
randomised controlled trial (RCT) models face 
particular challenges in the approvals process. 
•	 Knowledge & Expertise: Retaining project 
team expertise was critical for successful 
project management. This underpinned many 
of the problems (e.g. recruiting and retaining 
patients) commonly associated with the 
conduct of all models of clinical research. 
However, skills shortages create particular 
difficulties for non-commercial and smaller 
commercial research organisations. 
•	 Networks & Strategy: Project management 
is reliant on the development 
of successful working 
relationships between the 
research organisation and other 
key groups within the sector. 
Each research organisation 
must shape their strategy 
for research to fit in with the 
UK strategic context and to 
facilitate successful networking 
with other stakeholder groups. 
•	 Incentives & Drivers: 
To develop and maintain 
a network of relationships, research 
organisations and policy makers must 
develop insight into what incentivises different 
organisations, communities and individuals 
to engage in clinical research. In practice 
this may require balancing dissimilar or even 
antagonistic actions. The heterogeneous 
groups that are critical to the UK’s clinical 
research sector require different levels of 
support to incentivise involvement with 
research projects.
The major findings were found to be: 
1.	 The major predictor of success in terms of 
completing a project on time, with sufficient 
patients and on budget, was the ability to 
retain a project team. 
2.	 This finding highlights the importance of local 
knowledge and expertise in managing clinical 
research in the UK. Project management 
requires the development of practical 
nuanced knowledge that develops through 
on-going relationships with stakeholders 
across numerous organisations and clinical 
sites. When project teams are disrupted, often 
much of this local knowledge is lost, adversely 
affecting project outcomes. 
3.	 Changes to the governance system that 
were introduced following implementation of 
the EU Clinical Trials Directive and Research 
Governance Framework appear to have 
had little effect on set-up time.  
For projects conducted over the 
last decade, the average time to 
prepare and submit an application, 
and receive an outcome for 
approvals was found to be 114 
days (R&D), 91 days (ethics) and 
77 days (regulatory). For projects 
that obtained approval from 2007 
onwards, the average time  to 
prepare and submit an application, 
and receive an outcome for 
approvals was found to be 102 
days (R&D), 90 days (ethics) and 83 
days (regulatory). These figures are significantly 
longer than MHRA and NRES figures on 
approvals, suggesting that preparation time 
continues to be a major challenge.
4.	 All research groups, other than pharmaceutical 
firms, experience significant difficulty in 
obtaining information, completing paperwork 
and ensuring that the features of their models 
of research correspond with the requirements 
for regulatory and R&D approval. 
5.	 The greatest impediments to conducting 
clinical research in the UK were considered 
by researchers and managers to be time 
and cost. In addition, R&D approval, contract 
negotiation and NHS research culture were 
also considered major impediments.  
66.	 There was considerable variation in the time 
taken to obtain R&D approval across the 
UK. In conjunction with problems of contract 
negotiation, this suggests that there remains 
considerable variation across NHS Trusts with 
respect to these two aspects of conducting 
clinical research.  
7.	 The regulatory and ethical approval processes 
are viewed as having improved in recent 
years. The introduction of the NIHR Integrated 
Research Application Scheme (IRAS) and 
the Coordinated System for gaining NHS 
Permission (CSP) were considered to be a 
significant improvement in terms of ease of 
conducting research in the UK.   
8.	 The development of productive relationships 
between research organisations and other 
stakeholder groups is influenced by the 
different drivers that promote involvement with 
a project. Research organisations need insight 
into how different organisations, communities 
and individuals are incentivised, which may in 
practice require balancing dissimilar or even 
antagonistic actions.  
9.	 Distinct features of NHS Trusts act as 
incentives for research organisations to select 
particular recruitment sites. The findings 
highlight that the resources provided by a 
site, and the reputation of a Trust for patient 
recruitment, together with the reputation of 
the lead clinician, were important aspects 
which influenced the selection of sites for the 
projects reported.  
10.	Clinical Researchers believed that their 
expertise of planning and designing the 
project, such as inclusion criteria & 
recruitment strategy and presenting an 
interesting topic, were more important factors 
for recruitment than explicit incentivisation 
through the provision of rewards, such as 
financial and non-financial remuneration. 
11.	Different types of research organisation have 
different priorities which influenced their 
motivation in developing a clinical research 
project. Financial reward was important 
for commercial groups. Research group 
reputation and informing UK policy were 
more important for non-commercial research.
The full report presents detailed findings as to 
the many different challenges that influence the 
ease of managing clinical research projects within 
the UK. It is proposed that it is constructive to 
consider the relationship between the macro-
level system that may generate operational 
and management challenges for the research 
organisation, and the issues experienced with 
the day-to-day management of clinical research 
projects. We suggest that the current system tends 
to operate as a ‘one size fits all model’, where 
projects that do not confirm to the features of the 
Randomised Clinical Trial (RCT) model of research 
experience greater challenges with overall project 
management. However, policy response to these 
challenges needs to recognise and support all 
the research groups that constitute the clinical 
research sector within the UK.
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8summary of findings
Over the last decade UK scientists, clinicians and 
industrialists have expressed growing concern 
about the ‘translational gap’ between basic 
scientific discovery and innovation that will benefit 
patients. High quality clinical research is key to 
closing this gap and underpins innovation and 
improvement in health services. Clinical research 
is also central to the UK’s pharmaceutical, 
biotechnology and medical devices industries, 
which combined are an essential component of 
the UK’s economy. Yet the UK clinical research 
base is increasingly under threat from global 
competition and the time and cost of research and 
development continues to be a major challenge. 
The successful management and organisation 
of clinical research projects will be pivotal to 
overcoming these challenges in the future. 
This summary report describes an overview of 
findings from a 2-year EPSRC-funded study1 
which was undertaken to systematically explore 
the challenges of organising and managing 
different models of clinical research in the UK 
context. The ease with which clinical research can 
be conducted is also strongly influenced by both 
the strategic/market environment and by national 
policy and regulation. 
In particular, this research was conducted 
following considerable changes within the 
last decade to the management of the clinical 
research process within the UK. Extensive 
modifications to the UK regulatory and 
governance approval processes have been 
implemented. Significant attention from UK 
strategists and policy makers has also brought 
greater government investment into healthcare 
research, and catalysed the development of 
numerous initiatives which have influenced the UK 
context within which clinical research projects are 
organised. These macro institutional factors can  
 
1  “The Management & Organisation of Clinical Trials” (RIBK 9223) - The research 
was funded by the Engineering and Physical Sciences Research Council (EPSRC) via 
the Warwick Innovative Manufacturing Research Centre.
pose major coordination challenges for the  
successful management of clinical research 
projects at the micro level. 
This multilevel research study identified and 
mapped the macro-level issues surrounding 
clinical research in the UK, and systematically 
explored how these influenced the organisation of 
research and project management at the micro-
level. The purpose of this research was to identify
the key social, organisational and managerial 
factors that influence the management of clinical 
research projects. 
Specifically this research aimed to:
•	 Map alternative models of clinical research 
and identify the key challenges they generate, 
from the perspectives of the different research 
groups and key actors.
•	 Identify the macro institutional and policy drivers 
that frame the strategic environment within 
which research is conducted within the UK.
•	 Identify the barriers and enablers influencing 
the day-to-day management and organisation 
of clinical research projects within the UK.
•	 Explore the relationship between the macro-
level context and the day-to-day challenges 
associated with managing different models of 
research.
The findings inform understanding of how and 
why clinical research projects succeed or fail and 
what kinds of management and organisation 
are required to support success. We report 
on the completion rates of UK clinical research 
projects included in our study. The challenges 
of managing and organising clinical research 
are addressed across 4 major themes, and 
associated recommendations on how policy 
makers and clinical research communities might 
tackle these challenges are presented.
9Research Design
The study employed a multi-method design 
incorporating:
• A systematic literature review of previous work 
in this area, generating 129 core articles found 
from a total of 5,191.
• 57 interviews with key stakeholders which 
focused on the challenges of conducting 
different types of clinical research in the UK.
• A large scale survey generating data on the 
management of 247 clinical research projects 
conducted in the UK. This report details 
researchers’ own experiences of conducting 
one clinical research project, together with 
their perceptions about the current UK clinical 
research context.
The survey generated data about researchers’ 
experiences of setting-up and conducting 247 
clinical research projects and trials. The majority 
of the responses depict recent experiences of 
managing projects, with 63% of projects reported 
commencing during or after 2006. However, the 
design of the survey also enabled the collection 
of a representative sample of projects that took 
place earlier than this date. These data provide 
baseline data that help to show how changes in 
the UK context have influenced the management 
of projects over time.
The survey gathered behavioural data on the 
management and outcomes of clinical research 
projects as well as attitudinal data on barriers and 
enablers. The former are important in lending 
support (or otherwise) to the many personal theories 
and questions that abound around what predicts 
clinical research outcomes. The latter are important 
in assessing perceptions amongst different groups 
on how easy it is to conduct clinical research in the 
UK. These perceptions are important since they 
will influence the willingness of certain groups to 
participate in clinical research, even where they may 
not concur with facts and figures and perceived 
wisdom on governance arrangements.
Sample profile:
•	 27% of the projects were led by 
pharmaceutical organisations, and 16% by 
other commercial groups, including medical 
devices, biotechnology & start-up companies 
and contract research organisations. 57% 
of the projects were led by non-commercial 
research organisations, including university 
(40%), NHS and charity research groups. 
•	 56% of the projects were focused on 
medicines research, 11% were for medical 
devices or surgical studies, 15% focused on 
complex interventions and 18% focused on 
service & healthcare evaluation.
•	 83% of the projects led by commercial 
organisations were medicines trials. Projects 
led by non-commercial groups were more 
heterogeneous - 36% focused on medicines, 
9% on medical devices or surgical studies, 
26% on complex interventions and 29% on 
service & healthcare evaluation projects.
•	 26% of projects were focused on cancer 
research, 26% focused on either respiratory, 
cardiovascular, stroke or diabetes diseases. 
The remaining 48% covered many other 
disease areas. 
•	 16% of projects obtained regulatory approval 
before May 2004, 31% between May 2004 
and the end of 2006, and 53% obtained 
regulatory approval from 2007 onwards.
Project outcomes
There has been an overall improvement in the 
proportion of projects that complete within time 
over the last decade. The project set-up stage 
however continues to be a significant challenge, 
with the major improvement associated with 
improvements in time to recruit patients. That 
said, there is a slight drop in the proportion 
of projects from 2004 onwards that reach the 
anticipated recruitment target expected from UK 
sites within agreed time frames. The latter findings 
reflect an overall change in project management 
strategy; there is now greater pressure to 
conclude a project, even when it has not recruited 
to target, rather than to provide additional time to 
recruit further patients.
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The findings reveal that projects led by 
pharmaceutical companies were more 
likely to complete on time and to patient 
recruitment targets as compared to other 
commercial organisations and to projects led 
by non-commercial research groups. 45% of 
pharmaceutical-led projects completed on time, 
compared with 32% of non-commercial studies, 
and 24% of projects led by other commercial 
organisations.
Commercial organisations, other than 
pharmaceutical companies, experience greater 
difficulties completing within budget, with only 
48% of projects completing on budget and 
17% running over-budget by more than 50%. 
This compares with 68% of pharmaceutical-
led projects, and 64% of projects led by non-
commercial organisations completing on budget. 
Extremely few projects run by these groups were 
considerably over budget with only around 10% 
running more than 20% over budget.
Different types of research organisation 
experience different kinds of financial and 
budgetary pressures.  Respondents from 
projects led by commercial organisations found 
that budget pressures considerably influenced 
the ease of contract negotiation with NHS sites. 
Respondents from non-commercial organisations 
believed that financial issues adversely affected 
their ability to retain staff following completion of a 
project. 
The results from non-linear multivariate regression 
analysis models identified that retaining a project 
team is a critical predictor of overall project 
completion, and influences the ability to recruit 
to target. Ease of contract negotiation also 
accounted for much of the variability in project 
completion, and also influenced the overall patient 
recruitment levels that were achieved.
From the analysis of the data derived from both 
phases of this study, the greatest challenges 
affecting the management of clinical research 
were found around four areas:
•	 Regulation & Governance
•	 Knowledge & Expertise
•	 Networks & Strategy
•	 Incentives & Drivers
Regulation & Governance
Understanding, and successfully obtaining, the 
necessary regulatory approvals and governance 
permissions was identified as a particular 
challenge for project management. Projects 
led by different types of research organisation 
experienced varied challenges in this regard.  We 
suggest that the current system tends to operate 
as a ‘one size fits all model’, where projects 
that do not conform to a model of research 
that entails Randomised Clinical Trials (RCTs) 
experience greater difficulty obtaining regulatory 
& governance approvals. As non commercial 
groups are more likely to engage in non-standard 
clinical research models, they also experience 
greater challenges overall in securing approvals.
Changes to the regulatory & governance approvals 
system that were introduced in 2004 following 
implementation of the EU Clinical Trials Directive 
and the creation of the Research Governance 
Framework in 2001 have had little effect on 
overall set-up time. Since 2004, the duration 
required for researchers to prepare the necessary 
documentation and gain regulatory approval has 
increased slightly. The time taken to complete ethical 
approval has not changed, whilst the time taken for 
obtaining R&D approval has noticeably dropped. 
For projects conducted over the last decade, 
the average time to prepare and submit an 
application, and receive an outcome for approvals 
was found to be 114 days (R&D), 91 days 
(ethics) and 77 days (regulatory). For projects 
that obtained approval from 2007 onwards, 
the average time  to prepare and submit an 
application, and receive an outcome for approvals 
was found to be 102 days (R&D), 90 days (ethics) 
and 83 days (regulatory). These figures are 
significantly longer than MHRA and NRES figures 
on approvals, suggesting that preparation time 
continues to be a major challenge.
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Commercial research organisations experience 
a higher proportion of regulatory and ethical 
applications approved following first submissions 
(81% & 73%, respectively), compared with non-
commercial organisations (76% & 65%). The 
overall time taken to prepare, submit and receive 
an outcome for ethical approval was also lower for 
commercial organisations (81 days) than for non-
commercial research groups (100 days). Both groups 
reported similar regulatory approval durations (80 & 
82 days). Commercial groups experienced a longer 
time to prepare, submit, and obtain NHS Trusts R&D 
permissions than non-commercial groups (118 days 
compared with 112 days).
 
All research groups, other than pharmaceutical 
firms, experience significant difficulty in obtaining 
information, completing paperwork and ensuring that 
the features of their models of research correspond 
with the approval requirements for regulatory and 
R&D approval. This is less to do with the amount 
of information available and more to do with a 
proliferation of varied and new sources of information, 
some of which is seen to contain apparently 
conflicting advice. Commercial organisations often 
have dedicated resources to handle the submission 
process and so complete it more efficiently than non-
commercial research groups. 
Whilst changes in the regulatory and approvals 
system have been welcomed, some research 
groups perceive the current system as overly 
cumbersome due to an increase in the 
information and documentation that was required 
to satisfy legal and governance framework 
requirements. Certain research groups, such 
as consultant-led non-commercial projects had 
previously received regulatory exemptions, but 
after 2004 were required to apply for Clinical Trials 
Authorisation. This will account for much of the 
increase revealed by the above findings. 
The introduction of several initiatives, including the 
Integrated Research Application Scheme (IRAS), 
Coordinated Sign-off Procedure (CSP), Research 
Passport Scheme and the Bipartite/ Tripartite  
model clinical trial/ investigation agreements 
(mCTA/ mCIA) for commercial NHS collaboration, 
which are all aimed at improving the management 
of the set-up of projects are considered to be a 
significant improvement.  However, respondents 
stressed that only time would prove the actual 
effect of these initiatives, and whether this would 
in practice improve the process of engagement 
with NHS Trusts. Some argue that the approvals 
and monitoring systems need to focus more 
heavily on risk-based assessment of different 
models of research than on a highly standardised 
and prescribed approach.
The findings highlight that additional challenges 
are experienced when research does not 
conform to a standard RCT model, as it can be 
more difficult to fit research that exhibits non-
typical features with the standard paperwork 
and requirements of the approval system. 
Particular types of research which are valuable 
for supporting UK healthcare, such as essential 
medicines, acute & rare diseases, preventions 
research, and healthcare & service evaluation 
are less likely to conform to the features of the 
RCT model. These projects typically have greater 
challenges around managing patient recruitment 
and often use non-typical (non RCT) approaches, 
such as non-standard identification and consent 
processes to address these issues. 
In addition, late phase and post-marketing 
medicines research have longer ethical and 
R&D approval times compared with early phase 
research. Cancer research projects have longer 
R&D approval times, perhaps reflecting the 
particular liability concerns associated with this 
type of research.  
Overall, many researchers reported that they felt 
discouraged from including innovative features 
that were non-typical in applications to review 
bodies (e.g. incorporating novel recruitment 
methods). They felt that this would potentially 
increase the overall time taken to obtain 
approvals, as they would need to engage in 
additional discussion to justify their approach, 
and it was more likely that the application would 
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require re-submission.
Recommendations
i. The process for obtaining R&D approval from 
NHS Research Governance offices should be 
streamlined and made transparent.
ii. Performance data on R&D approval times 
for different NHS Trusts should be publically 
available for comparison 
iii. Standard documentation and information 
should be used across all NHS Trusts, with a 
guaranteed turn-around for decisions.
iv. Information on how to obtain approvals 
(including regulatory, ethics and R&D) should 
be provided in the form of a ‘one-stop-
shop’, with clearly signposted pathways for 
different models of research. Applicants 
should demonstrate they have consulted this 
information.
v. Examples of completed documentation (such 
as the ‘mock forms’ for a medicines and 
biotechnology product which are provided by 
the MHRA) should be provided by approval 
bodies for different models of research.
vi. The regulatory & governance system needs 
to reflect the particular risks and endemic 
features of different models of research. 
Training for committee members should 
include greater detail about how to assess the 
risks of different models of research. 
vii. The system of ‘flagged’ ethics committees for 
medical devices should be further extended 
with dedicated ethics committees being set 
up for other different models of research.
viii. The regulatory & governance system should 
actively encourage the inclusion of innovative 
forms of research. There should be different 
routes provided through forms, and greater 
flexibility to include novel approaches. 
ix. Members of approval bodies should 
receive training in how to assess novel 
approaches for research design to ensure 
that assessment of non-standard research 
features accurately assesses the risk.
Knowledge & Expertise
The survey data depict that retaining a project 
team is one of the most important aspects 
that influenced whether a project successfully 
recruited the required sample size and finished 
on time. Individual team members’ expertise 
is extremely important for successful project 
management, as often this is very practical, 
tacit knowledge that can only be obtained 
through experience and the development of 
working relationships with individuals from many 
organisations. 
The importance of local knowledge and 
expertise is emphasised as critical for successful 
management of clinical projects in the UK. Whilst 
helpful, knowledge from written, highly codified 
sources - such as information provided by 
websites or documentary sources – is not in itself 
sufficient. Instead project management requires 
the development of practical, nuanced knowledge 
that develops through on-going relationships with 
stakeholders across numerous organisations and 
clinical sites. Often clinical research nurses are 
essential conduits of local knowledge. When 
project teams are disrupted, much of this local, 
tacit knowledge may be lost, which can adversely 
affect project outcomes. The disruption of project 
teams is more likely in non commercial research 
projects that rely on contract funding.
There are many different sources from which 
researchers can access support and information 
to help develop their own expertise and to assist 
with project management. However, again, 
challenges arise not because the information 
is not available, but because it is not in an 
appropriate form. An overabundance of sources 
actually makes it difficult for researchers to work 
out what is current ‘state of the art’ advice. Many 
sources of information also assume a certain level 
of expertise, and provide information which is too 
specialised.
Support and advice from patient groups and 
charities is viewed as highly useful in developing 
and managing clinical research. However, actual 
contact with these groups by researchers is 
relatively low. These organisations can provide 
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sources of information that are very specific to the 
day-to-day reality of a condition. Research groups 
that do incorporate this support, such as through 
patient representation on advisory boards, have 
access to a different perspective enabling them 
to design projects that are more likely to be 
practically achievable and to avoid unnecessary 
time spent revisiting approvals in order to change 
protocols.
Whilst many of the recent initiatives aimed at 
improving the process over the last 2 years 
are viewed positively, challenges for managing 
projects still emerge because changes in the last 
decade mean that researchers continually need to 
obtain new expertise and knowledge. Confusion 
can arise from identifying what changes have 
been made and from the need to develop an 
understanding of how they can actually benefit 
from new initiatives.
Different organisations face varied challenges in 
terms of sourcing relevant skills and expertise. 
Smaller organisations are more reliant on 
individuals who have specific expertise within 
smaller teams, meaning that there is less flexibility 
with the management of projects to transfer 
individuals across projects when there are 
particular pressure points during a project. In 
addition, these organisations are vulnerable to loss 
of expertise if team members leave, as it is hard 
to preserve an organisational memory of the local 
knowledge that has been acquired by individuals.
Similarly, public-funded projects, typically in non-
commercial organisations, often employ research 
staff on fixed-term contracts. These types of 
research organisations are therefore particularly 
vulnerable to losses in expertise once a project 
draws to a close. Even if the team acquire further 
funding, which in principal would allow them to 
retain staff, there are often difficulties in agreeing 
contracts between funders and the research 
organisation in time to ensure continuity of staff 
contracts. This can lead to research staff with 
valuable local knowledge being forced to leave for 
alternate positions elsewhere. 
The geographical location of a research 
organisation can also influence access to 
the necessary skills required. If a research 
organisation is not based in an area where there 
is a strong clinical research base, there is a much 
smaller pool of individuals in the locality from 
which to select. Similarly, not being located in an 
area where there is high level of clinical research 
is also perceived to influence the attractiveness 
of an organisation to receive financial backing to 
support development of innovative, but inherently 
risky products, that are typical of the portfolio of 
biotech start-up companies.
Churn in employment can also encourage 
knowledge sharing across organisations as 
individuals bring with them experience of other sites 
and projects. However, this can act as a disincentive 
for organisations to develop training schemes for 
novice researchers. It can also encourage a turn-
over of more experienced staff as there are often 
incentives to transfer to other organisations.  
There are clearly many different roles and types 
of expertise required for clinical research. This 
complexity, coupled with a lack of an obvious 
career route in clinical research itself presents 
challenges. It was felt that clearer career 
trajectories in clinical research could help to 
narrow the skills gaps experienced in this sector. 
There were particular concerns regarding a 
skills shortage in experienced clinical research 
associates, clinical research nurses and project 
managers. Given the importance of local 
knowledge noted above, this adversely affects 
both commercial and non commercial research. 
In the UK public health system most projects, 
including commercial ones, rely to some degree 
on NHS staff. With regards research nurses, 
clinical research was not perceived as a ‘typical’ 
career path, major disincentives being that often 
the work was conducted on fixed-term contracts 
and that promotion opportunities were less. 
Hence it can be difficult to develop and retain 
experienced nurses.  It was also felt that support 
for clinical research varies widely across NHS 
Trusts and Executives.
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Recommendations
i. A dedicated portal for UK Clinical Research 
should be set up to assist less experienced 
clinical researchers in acquiring relevant 
knowledge and expertise.   The portal should 
ideally hold and up-date information about 
approval requirements, project management 
support, training provision, contract research 
services, professional and trade bodies, and 
charities and patient organisations.
ii. The support provided by recently 
implemented NIHR Research Design Services 
should be extended to actively support 
innovative and atypical research models that 
do not conform to the RCT approach. 
iii. A review of current training and accredited 
provision should be undertaken.
iv. A UK-wide strategy should be developed 
that identifies a career trajectory for clinical 
research. Career profiles of the range of 
roles engaged in clinical research should be 
developed.
v. Greater resources should be granted to 
patient and charity groups to enable these 
groups to increase the level of active support 
they can provide to research organisations.
vi. Research organisations should be 
incentivised to provide accredited training 
provision. 
vii. More flexible forms of employment (for 
example secondments, positions jointly 
funded by commercial and non-commercial 
organisations, or multi-host contracts) should 
be implemented to promote retention and 
ease skills shortages experienced by small 
organisations and groups reliant on fixed-term 
contracts. 
viii. Faster contracting should be a priority to help 
secure continuity across university and other 
publicly funded research projects. Bridge 
funding should be available for research staff 
experiencing temporary gaps in funding. 
Networks & Strategy
Project management is reliant on the 
development of successful working relationships 
between the research organisation and other 
key stakeholder groups. The findings highlight 
that challenges arise due to difficulties in creating 
and sustaining these networks. Research 
organisations need to build on expertise in 
the form of local, nuanced knowledge to 
facilitate the development of successful working 
relationships with other stakeholder groups. 
However, each research organisation will naturally 
be required to develop different strategies for 
forming these networks.
For most clinical research conducted within the 
UK, it is paramount that research organisations 
collaborate with NHS Trusts, as these are the 
gatekeepers to patients. There was considerable 
variation in the time taken to obtain R&D 
approval across the UK, despite attempts to 
develop more coordinated sign off and approvals 
systems. In conjunction with problems of contract 
negotiation, this suggests that there remains 
considerable variation across NHS Trusts in 
terms of their working relationships with particular 
research teams. 
The different perspectives that research 
organisations and Trusts hold regarding clinical 
research appear to have created some challenges. 
Researchers recognise that Trusts have a 
legal responsibility to protect their patients and 
resources. However, it was perceived that the 
disparate procedures in place to gain NHS 
permissions were a great impediment to 
successful project management. Some Trusts 
were ‘known’ to have bought-into streamlining and 
standardising this process, by for example, using 
standardised forms and reducing the amount 
of Trust-specific information requested. Thus 
researchers believed that it should not be legally 
problematic for other Trusts to also follow suit.
The findings highlight that many research 
organisations would ideally return to the same 
sites for subsequent research, demonstrating 
the value placed on previously established 
relationships and the challenges that can 
sometimes be faced when there is a need to 
develop new partnerships. Through maintaining 
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these relationships, researchers are able to 
develop the practical, nuanced knowledge that 
can only be obtained from actually working with 
individuals.  
The findings show that commercial organisations 
experience greater difficulty with developing 
relationships at the Trust level. This is because 
their contract negotiation is inherently more 
complex due to financial aspects that need to be 
agreed. Challenges experienced when smaller 
commercial organisations attempt to develop 
relationships with NHS sites emerge because 
often Trusts do not distinguish between this 
model of research and the global pharmaceutical 
sector, and do not recognise that they have lower 
financial resources.
Additional challenges emerge from competition 
between different research groups for use of 
NHS resources. As each Trust follows its own 
procedures, it can be more difficult to obtain 
knowledge about a new Trust’s procedures, 
meaning it can take more time to develop 
successful working relationships. Therefore, it 
can be difficult for Trusts (including both hospital 
and primary care) that do not have a reputation 
for previous research involvement, and have large 
numbers of patients not already involved in studies, 
to become part of the network of relationships that 
a research organisation works with.
Recent policy initiatives developed by the 
NIHR have the potential to support network 
relationships, providing more structured 
arrangement to bring together different 
stakeholder groups. Survey data indicated 
that recent NIHR policy initiatives aimed at 
streamlining the set-up stage of projects have 
been positively embraced. In particular the 
Integrated Research Application System (IRAS) 
and Co-ordinated System for gaining NHS 
Permissions (CSP) are perceived as having the 
potential to provide  significant improvements to 
the process. However a number of interviewees, 
whilst welcoming the idea of a research passport, 
and the development of bipartite/ tripartite model 
Clinical Trial/ Investigation Agreements (mCTA/ 
mCIA) between the NHS Trusts, Research 
Organisations (pharmaceutical/ medical devices 
companies) and Contract Research Organisations 
that would be valid across all Trusts, expressed 
some scepticism as to its practicability, and 
whether all Trusts would now follow similar 
practices.
The NIHR Clinical Research Network is an 
example of a prescribed network structure, 
which provides formalised links between 
different stakeholder groups. The National 
Cancer Research Network is considered to be 
very effective at supporting clinical research in 
this disease area. However, overall the survey 
data indicated that reaction to the effect of the 
creation of the NIHR Clinical Research Network 
on the management of clinical research projects 
was more temperate and restrained. Whilst the 
networks work well for the clinical discipline of 
cancer, the specific features of other diseases 
and historical underpinning of other clinical 
specialities present challenges for the adoption of 
this model across all clinical disciplines. Therefore, 
it is important to ascertain the features that 
make the cancer CRN successful, to inform the 
development of other networks. 
Clinical research organisations must engage 
with a variety of intermediary bodies, including 
professional & trade groups, patient groups, 
regulators and governance organisations, to try 
to gain the knowledge required to successfully 
manage a project. These provide a useful 
source of nuanced, tacit information. Contact 
with professional and trade groups strengthens 
network relationships with groups specifically 
relevant for the context of different models of 
research, as this can provide access to other 
relevant stakeholder groups. The findings 
suggest that, at times, research groups find it 
difficult to form relationships with patient groups 
and charities. However, when collaboration is 
developed, these types of groups can act as a 
bridge for developing connections between the 
public and researchers. 
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The diversity of research organisations influences 
how they can develop collaborations with other 
stakeholder groups, as the interests of all groups 
need to be balanced to create and maintain 
networks. Naturally, respondents from different 
types of research organisation will sometimes 
have different perceptions about the effect of 
policy initiatives and what the future focus of 
policy attention should be. The policy direction 
taken by different intermediary groups affects 
whether a network of relationships is successfully 
established and maintained. In particular, tensions 
can arise between balancing the support for 
commercial research (given its important role in 
significantly contributing to the UK economy), 
with the support that needs to be provided to non 
commercial organisations so that they can focus 
on particular UK-relevant health priorities.  
Different types of research organisation are 
inherently grounded in particular models of 
research which confer a specific context for how 
a network of relationships with other stakeholder 
groups is formed and maintained. All groups must 
have an appreciation of the underlying objectives 
and values of each respective organisation for 
successful partnerships to be created. However, 
research organisations must develop a strategy 
of how to work successfully with key UK groups 
(such as regulators, governance bodies and 
assessment groups such as NICE), and how to 
balance the UK context with a global network.
Recommendations
i. Further support is required to strengthen 
relationships between research organisations 
and the NHS. 
ii. NIHR initiatives to support the development 
of good relationships between the NHS 
and commercial research organisations are 
welcomed, and should be further reinforced 
and monitored as to their effects.
iii. Transparent information on NHS Trusts’ 
clinical research governance processes 
should be easily available.
iv. Information on NHS Trusts’ approval times 
and site-level recruitment and completion 
figures should be publically available.
v. There should be an evaluation of what 
makes effective clinical research networks, 
such as the Cancer CRN, to support the 
development of networks in other areas.
vi. Involvement with patient and charity groups 
should be promoted. There should be 
provision to cost charitable donations into 
publically funded research.
vii. All research organisations should be 
encouraged to work with NICE to ensure 
that research findings are tailored to the NHS 
context.
viii. A ‘community of practice’ for UK clinical 
research managers and research nurses 
should be fostered, in order to support the 
sharing of knowledge and expertise and 
build a strong identity and job market around 
UK clinical research. 
Incentives & Drivers
The development of productive relationships 
between research organisations and other 
stakeholder groups is influenced by the different 
drivers that promote involvement with a project.  
Research organisations need insight into how 
different organisations, communities and 
individuals are incentivised, which may in practice 
require balancing dissimilar or even antagonistic 
actions. The findings highlight that different types 
of research organisation have different drivers 
for clinical research, and thus respond differently 
to the support provided by UK strategists and 
policy makers.
Enrolling NHS sites necessitates skilful balancing of 
incentives at the organisational level when setting-
up contracts and obtaining permissions from 
R&D offices. It also needs attention to individual 
incentives in order to enlist clinicians to become site 
investigators and to commit clinical departments to 
recruit patients. The time taken for these negotiations, 
and the cost, could be difficult to predict accurately 
in advance and there was significant variation in ease 
of contract negotiation and approvals, which affected 
overall project management. 
18
Distinct features of NHS Trusts act as incentives 
for research organisations to select particular 
recruitment sites. The findings highlight that the 
resources provided by a site, and the reputation 
of a Trust for patient recruitment, together with 
the reputation of the lead clinician, were important 
aspects which influenced the selection of sites for 
the projects reported. 
Certain aspects are perceived to affect the level 
of recruitment at sites. The findings indicate 
that respondents believed that their expertise 
of planning and designing the project, such 
as inclusion criteria & recruitment strategy and 
presenting an interesting topic, were more 
important factors for recruitment than explicit 
incentivisation through the provision of rewards, 
such as financial and non-financial remuneration.
Data showed that researchers perceived that 
changes to the Consultant Contract through 
the 2002 framework (Department of Health, 
2002) and its subsequent amendments resulted 
in a change of emphasis on NHS Consultants’ 
participation in clinical research. Whilst the 
changes to the rewards system ultimately 
increased overall pay, it was felt that this contract 
conferred lower prominence on rewarding 
clinicians to participate in research.
The drivers for individuals to get involved in any 
role within a clinical research project vary. To 
successfully recruit and retain team members and 
collaborate with other key stakeholder groups, 
(such as clinicians based at clinical sites), requires 
a local insight into what drives different people 
to participate. This understanding is developed 
through experience, such as when a skilled 
project manager develops an appreciation of the 
practical level of involvement clinicians from sites 
actually want to have.
The findings indicate that certain features 
are considered to be more important drivers 
for why the research project was developed. 
Unsurprisingly, patient benefit is of high 
importance for all groups. In addition, further 
developing an existing area of expertise was rated 
highly, illustrating that organisations value the 
experience that team members have previously 
acquired, and that research organisations can 
subsequently leverage existing networks of 
relationships and expertise.
Different types of research organisation have 
different priorities which influenced their 
motivation in developing a clinical research 
project. Financial reward was obviously important 
for commercial groups. Enhancing a particular 
research group’s reputation and informing 
UK policy were more important motivators for 
non-commercial research teams. This reflects 
the importance to these groups of building a 
reputation for producing good quality research 
findings, in order to increase the likelihood of 
further funding.
The different drivers for conducting research 
are related to a tendency for different types of 
research organisations to develop projects based 
on different models of research. As different types 
of research organisation respond to different 
types of policy support, the decisions made 
by government strategists and policy makers 
creates support for certain groups, and ultimately 
influences the type of enterprise that takes place 
within the UK. 
Commercial organisations need to develop profit 
from their enterprise to be a viable business. 
Therefore they are skilled at efficient research 
that can be achieved through a streamlined 
RCT model based on a straightforward design. 
These organisations typically operate at a global 
level, at which the UK constitutes one of many 
possible locations for clinical research sites, and 
one of many target markets for the end-product. 
However, the UK is considered a good place 
to conduct clinical research projects that adopt 
the RCT model, as there are robust patient 
populations that will ultimately constitute a target 
market. The NHS as a potential market continues 
to be highly valued, such that often clinical 
research projects for late phase or marketed 
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innovations will be framed specifically with the UK 
context in mind. The UK also provides high levels 
of clinical expertise and access to highly qualified 
individuals.
Smaller biotech and start-up organisations 
however do experience difficulties. In general, this 
type of organisation is founded on developing 
a single or small number of clinical innovations 
which often carry a greater risk of failure. Whilst 
still aiming to generate profit, these smaller 
organisations do not have the same level of 
available resources and often experience skills 
shortages and lack expertise in project and 
business management.
Medical devices companies operate a different 
commercial model. They do not have the same 
type of patent cover as medicines so it is much 
easier to make amendments to the innovation. 
This can lead to different types of competition 
issues and time-pressures compared with 
medicines research, as there is less incentive 
to achieve a ‘first-to-market’ product. However, 
once marketing approval is received, these 
organisations are under increased pressure 
to continuously develop modifications and 
improvements to the product.
Many non-commercial research groups develop 
a research stream that is actively shaped by 
government funding priorities, such as the 
development of essential medicines which are 
not necessarily the focus of the commercial 
sector. These groups must develop expertise 
in managing projects that are typically more 
complicated and non-standard. For example, 
research into rare diseases and acute diseases 
presents inherent challenges for project 
management as there is generally a smaller 
patient population from which to recruit. However, 
the findings demonstrate that these types of 
projects achieve lower levels of recruitment. 
As this type of research does not necessarily 
conform to the RCT model, policy support and 
development would be welcomed to further 
promote this particularly valuable clinical research.
Recommendations:
i. NHS Trusts need to be flexible in how they 
negotiate contracts and permissions with 
different types of research organisation which 
reflect the different incentives that need to be 
offered. In particular, Trusts should recognise 
the specific financial and resource constraints 
experienced by smaller commercial 
organisations.
ii. Incentives to encourage greater NHS 
involvement in clinical research need to be 
targeted at different levels of the NHS: the 
organisational-level, site-level and individual-
level.
o	 All Trusts should be strongly encouraged 
to ‘buy into’ initiatives to develop a 
streamlined consistent system of approval 
and access. 
o	 Trusts should promote participation of 
clinical departments in clinical research, 
and ensure that benefits are directly 
received from this involvement.
o	 Greater attention should be given to 
encouraging the active involvement of 
clinicians as lead investigators in clinical 
research projects.
iii. Research conducted by pharmaceutical 
organisations can be supported through policy 
initiatives that encourage approval bodies and 
NHS Trusts to participate in a generic and 
streamlined procedure for the set-up of projects, 
and for clinical sites to increase the efficiency 
with which they recruit patients.
iv. Smaller commercial organisations can be 
supported through the development of a 
national network of support organisations 
that could provide expertise in areas such 
as project management, legal and regulatory 
issues and business management, which 
these organisations typically lack.
v. Research conducted by the non-commercial 
sector needs to be incentivised through the 
availability of public funding that supports 
projects which support the UK’s healthcare 
needs. These research groups require more 
flexible forms of employment to retain existing 
contract research staff.
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Challenges of managing clinical 
research in the UK
The full report presents detailed findings as to the 
many different challenges that influence the ease of 
managing clinical research projects within the UK. 
Time and cost continue to be seen as significant 
impediments to UK clinical research.  However, 
our study showed further that retaining a project 
team, R&D approval, contract negotiation and 
NHS research culture were also seen as major 
impediments. 
Respondents from different types of organisations 
had differing opinions about the current impediments 
that influence the management of clinical research 
in the UK. Respondents from pharmaceutical 
organisations perceive aspects such as patient 
safety, obtaining funding and obtaining ethical 
approval as not being an impediment to their 
research management. Whilst time and cost issues 
were viewed as important by researchers from all 
organisations, they were perceived as particularly 
important by respondents from pharmaceutical, 
and other commercial organisations. Whilst 
respondents from all organisations perceived 
obtaining R&D approval as a great impediment, this 
was particularly marked for pharmaceutical, other 
commercial and university/ academic research 
groups. The respondents from university and other 
non-commercial organisations rated funding as a 
particularly significant impediment, which reflects their 
reliance on external finance for projects.
Respondents from commercial organisations 
identified time and cost, and other aspects that 
reflect efficiency concerns such as R&D approval 
and contract negotiation as significant impediments. 
However, relative to other research organisations, 
pharmaceutical companies experience less difficulty 
with completing projects on time. Nevertheless 
this group are most directly influenced by global 
pressures. It should therefore be recognised that 
comparisons of their experiences of managing 
projects should not necessarily be made with other 
UK research organisations, but rather with other 
global enterprises. 
This study was conducted in the context of 
considerable changes to the UK system within which 
clinical research is organised and managed. Major 
alterations to the regulatory & governance approval 
process have occurred, and considerable attention 
from UK strategists and policy makers has resulted 
in the implementation of numerous initiatives that 
ultimately aim to improve the UK environment within 
which clinical research is conducted. However, these 
have also changed the context within which research 
is organised and managed within the UK.
Our findings suggest that it is constructive to consider 
the relationship between macro-level issues that 
possibly generate operational and management 
challenges for the research organisation, and the 
issues experienced with the day-to-day management 
of clinical research projects. A systematic literature 
review was used initially as a tool to identify the types 
of challenges that influence the management and 
organisation of clinical research. This synthesis of 
the literature supported the development of a two-
tier model categorising macro-level and micro-level 
issues that affect the management of clinical research 
within the UK. This distinction can be an important 
aid for policy review in terms of how to respond to the 
different types of issues that exist, as the first group 
reflects issues that stem from beyond the research 
organisation and influence the overall research 
environment (e.g. policy initiatives and regulation 
& governance), whilst micro-level issues reflect 
challenges that are generated at the project-level and 
influence the management of research at a day-to-
day level. 
The detailed findings presented in the main report 
highlight numerous challenges that influence the 
successful management of clinical research projects 
within the UK. It has been emphasised that the 
conclusions
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policy response to these challenges needs to 
recognise and support all the research groups that 
constitute the clinical research sector within the UK, 
in order to promote ‘UK PLC’. Clinical research is a 
knowledge-intensive industry and its future is reliant 
on developing and nurturing the expertise that this 
sector is based upon. However, the findings underline 
the fact that many of the challenges of conducting 
clinical research are compounded because of 
the complex array of different stakeholder groups 
involved and the different models of research that are 
being conducted. This presents challenges for policy 
makers in balancing the support required for different 
types of research organisation, whilst more generally 
promoting the clinical research sector within the UK.
At best the system is a ‘one size fits all model’, where 
what is perceived as good research is framed by 
a standard RCT model. Other models of research 
experience considerable challenges.  This has 
the potential to discourage research groups from 
developing innovative approaches to clinical research 
which are based on atypical features that might 
differ considerably from a standard RCT. That is 
not to say, however, that large commercial groups 
do not experience challenges as they experience 
the greatest pressures from the global context in 
which they operate, and often feel marginalised by 
other groups within the healthcare sector. Policy 
makers should recognise that different clinical groups 
require different levels and types of support, and 
should also be aware that strategic changes to the 
UK environment may inadvertently create additional 
challenges for the organisation and management of 
particular types of research.
The findings presented in this report provide 
particularly valuable insight into how certain groups 
view particular aspects of the process of managing 
clinical research projects. Other stakeholder 
groups, including policy makers and the regulatory 
& governance approval groups should recognise 
that these attitudes exist, even if they debate the 
legitimacy of these views from the context of their 
own remit and the actions that they have taken. This 
is important because attitudes shape whether people 
become involved in research. In short, if researchers 
see the UK context as too challenging, then they may 
choose to conduct projects elsewhere, or cease to 
engage in clinical research.  However, it also needs 
to be recognised that attitudes and perceptions 
of the effects of very recent initiatives,  such as the 
introduction of the UKCRN, are not reflective of actual 
behaviours at a project level, and in-depth research 
should be undertaken to explore their actual  impact  
on  the successful management of clinical research 
projects. It is vital that research is undertaken to 
generate in-depth findings regarding the actual 
experiences of managing clinical research within the 
UK, which survey data, however detailed cannot 
adequately capture.
This report has explored the challenges experienced 
when managing clinical research projects under four 
themes. These themes are interlinked and the issues 
that have been highlighted over-lap these areas. For 
example, challenges related to a lack of expertise 
are also inherently linked to the incentives to recruit 
and retain project team members. Nevertheless, 
it is important to reiterate that it is the macro-level 
context, including global and market pressures, 
the UK strategic emphasis and policy initiatives, 
ethical principles and the regulatory & governance 
framework, that influence how the challenges 
associated with  these four themes are experienced 
in the day-to-day management of projects.
Figure (i) Schematic model depicting the UK clinical 
research system 
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